MPT0E028 is an orally active and selective inhibitor of HDAC (IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2, and HDAC6, respectively). MPT0E028 has good anticancer activity. MPT0E028 decreases the viability of B-cell lymphomas by inducing apoptosis
Cellocidin is a potent gammaherpesvirus-associated B-lymphomas growth inhibitor. It acts through the activation of both the NF-κB and c-Myc-mediated signaling pathways.
NSC10010 hydrochloride is an effective growth inhibitor for gammaherpesvirus-associated B-lymphomas. It acts through activation of both the NF-κB and c-Myc-mediated signaling pathways.
5-Hydroxy-8-methoxypsoralen (5-Hydroxyxanthotoxin) is a metabolite derived from Xanthotoxin, which acts as a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450). It is employed as an agent for the treatment of psoriasis, eczema, vitiligo, and certain cutaneous Lymphomas, in combination with phototherapy involving exposure to sunlight.
Tubulin polymerization-IN-37 is a potent inhibitor (IC50: 2.3 μΜ) of tubulin polymerization by binding specifically to the colchicine site of tubulin and preventing colchicine binding. It has potential applications in cancer research, notably for lymphomas [1].
KC-11404 is an LTB4 inhibitor for the treatment of b-cell leukemias and lymphomas, potently inhibiting histamine, platelet activating factor and 5-lipoxygenase.
CUDC-907 mesylate is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multiple myeloma, breast cancer and other malignancies.